Healthcare Global Enterprises Ltd
Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.[1]
- Market Cap ₹ 10,021 Cr.
- Current Price ₹ 671
- High / Low ₹ 800 / 513
- Stock P/E 152
- Book Value ₹ 107
- Dividend Yield 0.00 %
- ROCE 6.14 %
- ROE 4.72 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 6.24 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Tax rate seems low
- Company has a low return on equity of 2.90% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.14%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 BSE Hospitals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 420 | 471 | 545 | 586 | 640 | 688 | 609 | 850 | 1,006 | 1,171 | 1,277 | 1,365 | |
| 364 | 407 | 462 | 498 | 546 | 573 | 535 | 703 | 824 | 970 | 1,065 | 1,124 | |
| Operating Profit | 56 | 64 | 83 | 88 | 94 | 116 | 74 | 147 | 181 | 201 | 211 | 242 |
| OPM % | 13% | 14% | 15% | 15% | 15% | 17% | 12% | 17% | 18% | 17% | 17% | 18% |
| 0 | -1 | 7 | 19 | 13 | -19 | -129 | 65 | 7 | 0 | 4 | -26 | |
| Interest | 32 | 34 | 16 | 27 | 48 | 83 | 63 | 43 | 41 | 50 | 84 | 86 |
| Depreciation | 33 | 37 | 44 | 44 | 47 | 79 | 87 | 88 | 89 | 97 | 111 | 120 |
| Profit before tax | -8 | -9 | 29 | 37 | 13 | -65 | -205 | 81 | 58 | 54 | 20 | 10 |
| Tax % | -69% | -45% | 34% | 32% | 42% | -19% | -7% | 53% | 30% | 39% | 82% | -52% |
| -2 | -5 | 19 | 25 | 7 | -53 | -192 | 38 | 40 | 33 | 4 | 15 | |
| EPS in Rs | -0.32 | -0.52 | 2.15 | 2.71 | 0.78 | -5.68 | -14.43 | 2.60 | 2.73 | 2.22 | 0.24 | 0.98 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 18% |
| 3 Years: | 11% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 88% |
| 5 Years: | 30% |
| 3 Years: | 15% |
| TTM: | 3994% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 22% |
| 3 Years: | 26% |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 3% |
| 3 Years: | 3% |
| Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 | 149 |
| Reserves | 202 | 435 | 459 | 552 | 557 | 526 | 798 | 959 | 1,006 | 1,042 | 1,052 | 1,455 |
| 311 | 194 | 218 | 264 | 422 | 827 | 481 | 349 | 347 | 758 | 1,118 | 1,022 | |
| 107 | 136 | 159 | 210 | 337 | 328 | 169 | 197 | 237 | 299 | 295 | 291 | |
| Total Liabilities | 690 | 850 | 923 | 1,112 | 1,404 | 1,769 | 1,575 | 1,644 | 1,730 | 2,239 | 2,604 | 2,917 |
| 405 | 431 | 442 | 492 | 547 | 914 | 745 | 774 | 788 | 974 | 1,038 | 1,122 | |
| CWIP | 28 | 29 | 33 | 79 | 104 | 44 | 28 | 5 | 9 | 36 | 23 | 14 |
| Investments | 84 | 155 | 141 | 219 | 299 | 316 | 366 | 439 | 475 | 506 | 696 | 704 |
| 173 | 235 | 306 | 322 | 454 | 495 | 436 | 426 | 458 | 722 | 847 | 1,078 | |
| Total Assets | 690 | 850 | 923 | 1,112 | 1,404 | 1,769 | 1,575 | 1,644 | 1,730 | 2,239 | 2,604 | 2,917 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | 58 | 54 | 66 | 87 | 86 | 71 | 124 | 130 | 209 | 146 | 160 | |
| -74 | -86 | -73 | -185 | -208 | -116 | -246 | 49 | -138 | -254 | -347 | -76 | |
| 22 | 120 | -14 | 91 | 66 | -3 | 236 | -41 | -42 | 96 | -42 | 336 | |
| Net Cash Flow | -1 | 92 | -33 | -27 | -55 | -32 | 61 | 132 | -49 | 51 | -243 | 421 |
| Free Cash Flow | -17 | -32 | 18 | -37 | -36 | 6 | 48 | 82 | 36 | 80 | 13 | 8 |
| CFO/OP | 90% | 102% | 74% | 74% | 120% | 92% | 41% | 95% | 81% | 121% | 78% | 70% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 54 | 67 | 79 | 83 | 81 | 88 | 69 | 77 | 69 | 75 | 70 |
| Inventory Days | 36 | 30 | 36 | 40 | 39 | 31 | 32 | 30 | 33 | 30 | 23 | 26 |
| Days Payable | 208 | 266 | 257 | 269 | 253 | 247 | 214 | 167 | 168 | 192 | 175 | 168 |
| Cash Conversion Cycle | -116 | -182 | -154 | -150 | -131 | -135 | -94 | -68 | -59 | -93 | -77 | -71 |
| Working Capital Days | -64 | -74 | -69 | -24 | -82 | -133 | 38 | 9 | 26 | -37 | -70 | -41 |
| ROCE % | 5% | 5% | 6% | 7% | 6% | 4% | 1% | 5% | 7% | 7% | 7% | 6% |
Insights
In beta| Mar 2010 | Mar 2015 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Average Occupancy Rate (AOR) % |
|
||||||||
| Capacity Beds (Installed) Beds |
|||||||||
| Number of Hospitals Hospitals |
|||||||||
| Number of LINACs LINACs |
|||||||||
| Operating Theatres OTs |
|||||||||
| ARPP (Average Revenue Per Patient, excl Fertility) INR per patient |
|||||||||
| IP Patient Volumes (excl Fertility) IP patients |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
27 Jul - Further to the intimation submitted to Stock Exchanges dated July 27, 2026, with respect to the meeting of the Board of the Company, to be …
-
Board Meeting Intimation for Considering And Approving Inter-Alia, The Unaudited Financial Results (Both Standalone And Consolidated) Of The Company For The Quarter Ended June 30, 2026 (''Financial Results'').
27 Jul - Board meeting on August 6, 2026 to approve Q1 FY27 unaudited standalone and consolidated results.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jul - Newspaper Advertisement in respect of Special Window for Transfer and Dematerialisation of Physical Securities of the Company.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 9 Jul
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Jul - Regulation 74(5) certificate filed for demat/remat requests in quarter ended June 30, 2026.
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Feb 2026TranscriptAI SummaryPPT
-
Dec 2025Transcript PPT REC
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT
-
Mar 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptAI SummaryPPT
-
Oct 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020Transcript PPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptAI SummaryPPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
-
May 2018Transcript PPT
-
Feb 2018TranscriptPPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
Jun 2016Transcript PPT
Service Offering
The Company is a provider of specialty healthcare focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centers licensed by the AERB. It also provides fertility treatment under our “Milann” brand. [1]